Clinical trials: Brachytherapy, open to volunteers
Hepatocellular Carcinoma (HCC)
A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.
This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer.
- Trial name
- NCT07663487
- Testing
- SIR-Spheres Selectively Delivered to Liver Tumor
- Volunteers
- 78 people
- Sponsor
- Sirtex Medical
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Cervical Cancer, Uterine Cancer
Image-Guided Gynecologic Brachytherapy
This research is being done to evaluate multimodality imaging, including magnetic resonance imaging-guided therapy (MRT), as a possible treatment for gynecologic cancers.
- Conditions
- Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
- Trial name
- NCT02993900
- Testing
- Image-Guided Brachytherapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Skin Cancer, Cutaneous Tumor
Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for Malignant Cutaneous Tumors
- Conditions
- Skin Cancer, Cutaneous Tumor, Cutaneous Metastasis
- Trial name
- NCT04068155
- Testing
- DaRT- Diffusing Alpha-emitters Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Alpha Tau Medical LTD.
Prostate Cancer
Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial
This project aims to compare the changes in the urinary quality of life (QoL) following focal high dose-rate brachytherapy (HDR-BT) boost to stereotactic ablative radiotherapy (SABR), compared to standard whole gland HDR-BT…
- Trial name
- FORWARD (NCT07300566)
- Testing
- Standard Arm: Whole Gland High Dose Rate Brachytherapy Boost, Experimental Arm: Focal High Dose Rate Brachytherapy Boost
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Joelle Helou
Pancreatic Neoplasm, Digestive System Neoplasm
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination…
- Conditions
- Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
- Trial name
- OSPREY (NCT04493632)
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 500 people
- Sponsor
- OncoSil Medical Limited
Extrahepatic Cholangiocarcinoma
Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable Extrahepatic Cholangiocarcinoma
This is a prospective, single-arm, interventional clinical study. The purpose of this study is to evaluate the clinical efficacy and safety of Photodynamic Therapy (PDT) combined with a self-expandable radioactive particle-loaded…
- Trial name
- Photodynamic T (NCT07916870)
- Testing
- Hematoporphyrin Injection, Self-expandable radioactive particle-loaded biliary stent, Photodynamic Therapy (PDT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhai Wenlong
Prostate Cancer
Salvage HDR for Locally Recurrent Prostate Cancer
The study offers focal salvage brachytherapy for prostate cancer patients with a local recurrence after primary defintive radiotherapy
- Trial name
- PROSALBRA (NCT04231006)
- Testing
- High dose rate brachytherapy
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Recurrent Glioblastoma, Recurrent Gliomas
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
- Trial name
- NCT06910306
- Testing
- Device :DaRT seeds
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Uterine Cervical Neoplasms
Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy
This is a multicenter, prospective study aimed at providing information on the psychological effects (including post-traumatic stress symptoms) of utero-vaginal brachytherapy in patients with cervical cancer using…
- Trial name
- TRUST-GB (NCT07204535)
- Testing
- Prospective questionnaires
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Centre Paul Strauss
Prostate Cancer
Needle Localization During Prostate Brachytherapy Using Power Doppler Ultrasound
This study involves patients who are scheduled for standard care brachytherapy of focal tumours within the prostate, which is normally performed under standard 2-dimensional (2D) ultrasound guidance.
- Trial name
- NCT03861507
- Testing
- Prostate Brachytherapy
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Western University, Canada
Prostate Cancer
MRI-guided Locoregional SBRT Prostate Program
The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a Prostate Cancer Program will allow to reproduce the results obtained with state-of-the-art brachytherapy combined with EBRT with the added…
- Trial name
- NCT07132073
- Testing
- Brachytherapy + SBRT
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
SIRT and Peri-immunotherapy : a New Concept
The combination of selective internal radiation therapy (SIRT) with immunotherapy represents an innovative and potentially highly effective therapeutic strategy for the treatment of advanced-stage hepatocellular carcinoma (BCLC…
- Trial name
- IMSIRT (NCT06971237)
- Testing
- Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization, Atezolizumab ± Bevacizumab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psychological Distress
CARE-BI:a Pilot Study to Improve Patient Comfort and Reduce Psychological Distress During IA Removal
The goal of this research study is to learn about the rate of posttraumatic stress disorder (PTSD) experienced by women after undergoing gynecologic brachytherapy.
- Trial name
- NCT07335302
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Gynaecological Cancer
In Vivo Dosimetry for Brachytherapy Study
The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).
- Trial name
- NCT06863090
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- East and North Hertfordshire NHS Trust
Prostate Cancer, Radiotherapy Side Effect
Prostate Reirradiation Toxicity Outcomes Feasibility Study
The RO-PIP trial aims to determine the feasibility of recruitment to a trial randomising patients to salvage ultra-hypofractionated external beam radiotherapy or high dose rate brachytherapy and provide prospective data on…
- Trial name
- RO-PIP (NCT05614700)
- Testing
- Brachytherapy, Sterotactic Body Radiotherapy
- Volunteers
- 60 people
- Sponsor
- University of Leeds
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Unresectable Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
- Trial name
- NCT06909708
- Testing
- SIRT, cTACE
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongda Hospital
Gynecologic Cancer, Endometrial Cancer
3D Printed Custom Applicators for HDR BT (DISCO)
Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose…
- Conditions
- Gynecologic Cancer, Endometrial Cancer, Vaginal Cancer, Vulva Cancer
- Trial name
- NCT06432478
- Testing
- 3D-printed custom applicator
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Royal North Shore Hospital
Squamous Cell Carcinoma, Alpha Radiation
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Conditions
- Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
- Trial name
- DaRT (NCT06615635)
- Testing
- DaRT seeds
- Where
- 11 sites in United States, Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.